Hannah E. Fuchs
YOU?
Author Swipe
View article: Provider billing margin and cancer treatment selection: population based cohort study
Provider billing margin and cancer treatment selection: population based cohort study Open
Objective To estimate the association between the billing (profit) margin and clinical benefit of cancer treatments and use by oncologists. Design Retrospective population based cohort study Setting Population based sample using fee-for-se…
View article: Collaborating across sectors in service of open science, precision oncology, and patients: an overview of the AACR Project GENIE (Genomics Evidence Neoplasia Information Exchange) Biopharma Collaborative (BPC)
Collaborating across sectors in service of open science, precision oncology, and patients: an overview of the AACR Project GENIE (Genomics Evidence Neoplasia Information Exchange) Biopharma Collaborative (BPC) Open
The American Association for Cancer Research (AACR) Project GENIE (Genomics Evidence Neoplasia Information Exchange) Biopharma Collaborative (BPC) is a multi-phase, pre-competitive collaboration between 10 biopharmaceutical companies and s…
View article: Implementation Strategies to Promote Short-Course Radiation for Bone Metastases
Implementation Strategies to Promote Short-Course Radiation for Bone Metastases Open
Importance For patients with nonspine bone metastases, short-course radiotherapy (RT) can reduce patient burden without sacrificing clinical benefit. However, there is great variation in uptake of short-course RT across practice settings. …
View article: Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set
Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set Open
PURPOSE Observational clinicogenomic data sets, consisting of tumor next-generation sequencing (NGS) data linked to clinical records, are commonly used for cancer research. However, in real-world practice, oncologists frequently request NG…
View article: TABLE 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
TABLE 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Univariable and multivariable logistic regression models for associations between baseline characteristics and the presence of PM
View article: FIGURE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
FIGURE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
PFS from initiation of first-line cancer-directed regimen (A, PM vs. non-PM; B, PM only vs. PM and other sites vs. non-PM; C, stage IV: PM only vs. PM and other sites vs. non-PM; D, stage I–III with later development of distant metastasis:…
View article: TABLE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
TABLE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Frequencies of genomic alterations in tumor samples—Results are displayed for genomic alterations present in at least 7% of tumor specimens and tested in at least 20% of the tumor specimens, as well as NRAS and MED12. Frequencies do not re…
View article: Supplementary Figure 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Supplementary Figure 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Supplementary Figure 2. Oncoprint from patients without peritoneal metastasis
View article: FIGURE 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
FIGURE 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
OS from diagnosis of advanced disease (A, PM vs. non-PM; B, PM only vs. PM and other sites vs. non-PM; C, stage IV: PM vs. non-PM; D, stage I–III with later development of distant metastasis: PM vs. non-PM).
View article: FIGURE 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
FIGURE 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Flowchart of patient selection from GENIE BPC colorectal cancer registry.
View article: TABLE 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
TABLE 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Univariable and multivariable logistic regression models for associations between baseline characteristics and the presence of PM
View article: TABLE 4 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
TABLE 4 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Univariable and multivariable Cox proportional hazards models for OS
View article: TABLE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
TABLE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Frequencies of genomic alterations in tumor samples—Results are displayed for genomic alterations present in at least 7% of tumor specimens and tested in at least 20% of the tumor specimens, as well as NRAS and MED12. Frequencies do not re…
View article: TABLE 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
TABLE 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Clinical and pathologic characteristics of the study cohort
View article: FIGURE 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
FIGURE 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Flowchart of patient selection from GENIE BPC colorectal cancer registry.
View article: Supplementary Tables from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Supplementary Tables from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Supplementary Tables 1-9
View article: TABLE 4 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
TABLE 4 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Univariable and multivariable Cox proportional hazards models for OS
View article: Data from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Data from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Peritoneal metastases (PM) are common in metastatic colorectal cancer (mCRC). We aimed to characterize patients with mCRC and PM from a clinical and molecular perspective using the American Association of Cancer Research Genomics Evidence …
View article: Supplementary Figure 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Supplementary Figure 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Supplementary Figure 2. Oncoprint from patients without peritoneal metastasis
View article: Supplementary Tables from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Supplementary Tables from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Supplementary Tables 1-9
View article: Supplementary Figure 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Supplementary Figure 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Definitions of patient-level MSI and MMR statuses
View article: Supplementary Figure 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Supplementary Figure 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Definitions of patient-level MSI and MMR statuses
View article: TABLE 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
TABLE 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Clinical and pathologic characteristics of the study cohort
View article: Supplementary Figure 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Supplementary Figure 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Oncoprint of patients with peritoneal metastasis
View article: FIGURE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
FIGURE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
PFS from initiation of first-line cancer-directed regimen (A, PM vs. non-PM; B, PM only vs. PM and other sites vs. non-PM; C, stage IV: PM only vs. PM and other sites vs. non-PM; D, stage I–III with later development of distant metastasis:…
View article: Data from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Data from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Peritoneal metastases (PM) are common in metastatic colorectal cancer (mCRC). We aimed to characterize patients with mCRC and PM from a clinical and molecular perspective using the American Association of Cancer Research Genomics Evidence …
View article: FIGURE 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
FIGURE 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
OS from diagnosis of advanced disease (A, PM vs. non-PM; B, PM only vs. PM and other sites vs. non-PM; C, stage IV: PM vs. non-PM; D, stage I–III with later development of distant metastasis: PM vs. non-PM).
View article: Supplementary Figure 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Supplementary Figure 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Oncoprint of patients with peritoneal metastasis
View article: Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry Open
Peritoneal metastases (PM) are common in metastatic colorectal cancer (mCRC). We aimed to characterize patients with mCRC and PM from a clinical and molecular perspective using the American Association of Cancer Research Genomics Evidence …